37,618 Shares of iShares Biotechnology ETF $IBB Purchased by Geneva Partners LLC

Geneva Partners LLC purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 37,618 shares of the financial services provider’s stock, valued at approximately $8,020,000. iShares Biotechnology ETF makes up 2.4% of Geneva Partners LLC’s holdings, making the stock its 16th biggest position.

Other institutional investors have also recently made changes to their positions in the company. Bank of America Corp DE grew its stake in shares of iShares Biotechnology ETF by 10.8% during the 1st quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock valued at $1,225,767,000 after acquiring an additional 707,343 shares during the period. Royal Bank of Canada raised its stake in iShares Biotechnology ETF by 1.0% during the 1st quarter. Royal Bank of Canada now owns 737,128 shares of the financial services provider’s stock worth $124,464,000 after acquiring an additional 7,434 shares during the period. Albion Financial Group UT raised its stake in iShares Biotechnology ETF by 1.0% during the 3rd quarter. Albion Financial Group UT now owns 120,782 shares of the financial services provider’s stock worth $25,428,000 after acquiring an additional 1,147 shares during the period. Cetera Investment Advisers raised its stake in iShares Biotechnology ETF by 9.4% during the 1st quarter. Cetera Investment Advisers now owns 128,530 shares of the financial services provider’s stock worth $21,702,000 after acquiring an additional 10,994 shares during the period. Finally, Henshaw Capital LLC bought a new stake in iShares Biotechnology ETF during the 1st quarter worth approximately $20,262,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 0.5%

Shares of NASDAQ:IBB opened at $208.69 on Tuesday. iShares Biotechnology ETF has a 1-year low of $154.62 and a 1-year high of $217.12. The firm’s 50 day simple moving average is $207.81 and its two-hundred day simple moving average is $183.96.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 18th. Stockholders of record on Tuesday, September 15th were given a dividend of $0.0112 per share. This represents a $0.04 annualized dividend and a dividend yield of 0.0%. The ex-dividend date was Tuesday, September 15th. This is a negative change from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.